Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PA31 | ISIN: US68621F1021 | Ticker-Symbol: 2PQ
Frankfurt
23.04.24
21:55 Uhr
2,780 Euro
+0,020
+0,72 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ORGANOGENESIS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ORGANOGENESIS HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,7402,84023.04.
2,7802,80023.04.

Aktuelle News zur ORGANOGENESIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.04.Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 20243
03.04.Organogenesis Holdings Inc. - 8-K, Current Report1
03.04.Organogenesis Holdings Inc.: Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case101CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization...
► Artikel lesen
02.03.Why Organogenesis Holding Stock Plummeted by 18% Today2
01.03.Earnings call: Organogenesis anticipates return to revenue growth in 20241
29.02.Organogenesis Holdings Inc reports results for the quarter ended in December - Earnings Summary1
29.02.Organogenesis Holdings Inc. - 10-K, Annual Report1
29.02.Organogenesis Holdings GAAP EPS of $0.00 in-line, revenue of $99.7M misses by $9.35M1
29.02.Recap: Organogenesis Holdings Q4 Earnings1
29.02.Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance137CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
► Artikel lesen
28.02.Organogenesis Holdings Q4 2023 Earnings Preview1
28.02.A Preview Of Organogenesis Holdings' Earnings1
12.02.Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference1
09.02.Cantor starts Organogenesis at overweight, cites differentiated portfolio1
08.02.Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024-
07.02.Cantor Fitzgerald starts Organogenesis coverege with a $5 target-
10.11.23Earnings call: Organogenesis reports Q3 revenue drop, optimistic for future growth despite challenges1
10.11.23Organogenesis Holdings Inc reports results for the quarter ended in September - Earnings Summary1
09.11.23Organogenesis Holdings Inc. - 8-K, Current Report1
09.11.23Organogenesis Holdings Inc. - 10-Q, Quarterly Report1
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1